NFL Commissioner Roger Goodell said that he would consider letting NFL players use medical marijuana for concussion issues.

SAN JOSE, CALIFORNIA, UNITED STATES, September 2, 2014 /EINPresswire.com/ -- According to Daniel Kaplan of the Sports Business Journal, NFL Commissioner Roger Goodell said that he would consider letting NFL players use medical marijuana for concussion issues.
Goodell says if medical experts ever say medical marijuana would help with concussions then would consider allowing it.
— daniel kaplan (@dkaplanSBJ) January 23, 2014

A San Jose based cannabis pharmaceutical company is in the process of researching and developing a patented medical marijuana treatment named Knoxavarin, for a disease that commonly affects athletes who experience, chronic traumatic encephalopathy (CTE).

Emerald Strips Inc. subsidiary of Emerald Rush Holdings, a company based in Silicone Valley stated in an interview with their VP of new business development OJ Smith, stated that the company expects the federal government to open the doors for medical marijuana on a national scale within the next two years.

The biopharmaceutical company focused on commercializing novel therapeutics from its cannabinoid infused dissolving edible strips, and chewing gums has recently signed an agreement with Octavius Smith the patent inventor of Xanavarin, and are now poised to proceed with their second formulation of cannabis pharmaceuticals designed with the sports industry in mind.

According to OJ, “it’s a win, win situation!” One in which the drugs inventor, and Emerald Rush Holdings, parent company to Emerald Strips, can begin moving forward with developing its therapeutic and preventative treatments with Knoxavarin.

The drugs designer, Octavius Smith, said recently “I really began to become concerned with the brain of athletes once I found out my fathers dementia was due to sports. So my primary goal was to establish a treatment that is both therapeutic for athletes currently suffering from CTE, as well as a preventative for athletes now active in the sport.”

Octavius, who helped establish and actively consults a 55k member medical marijuana dispensary The Purple Lotus Patient Center in San Jose, mentions, "things took a more serious turn when his father, a 1956 Olympics boxing hopeful representing the USA and the Army, was diagnosed with CTE, pre-onset dementia due directly to his boxing career." While in Houston at his fathers house Octavius continued for over 2 years researching everything he could find to help his father. Just like NFL players, athletes in the boxing world suffers from multiple blows to the head causing CTE. "In the case of my father, although he like to brag he was never knocked out in his career, He had to admit he has been hit, and hit hard, throughout his boxing career." A fact that even the Veterans Administration had to admit to. They finally awarded him 100% disability because we established a direct connection between his boxing career, and his current condition.

Emerald Strips has made solid progress and is at the forefront of pharmaceutical grade marijuana R&D. Their formulations will address the needs of patients choosing to use concentrated cannabis extracts. This new patent provides that marijuana is a neuroprotectant and AChE inhibitor. This is what makes Knoxavarin a superior treatment for neurodegenerative conditions like CTE.

CTE’s national prominence is tied to a class action lawsuit again the National Football League. The lawsuit which was filed by retired players claims that the league willfully concealed the effects of continuous concussions. Originally a $765 million settlement was rejected by a federal judge for being insufficient in its amount to properly compensate players.

Dr. Jonathan Palmer research director for Emerald Strips continues, “the FDA Fast Track Designation is a designation that facilitates the development, and expedites the review, of drugs treating life-threatening condition. It usually takes 60 days for a reply.
The company expects to file an Fast Track Designation investigational new drug application with the FDA at the beginning of 2015, then proceed to phase 1 clinical trials.”

“Pure cannabinoid compounds has been delivered to our research facility where testing will begin immanently on Knoxavarin,” states Dr. Palmer. “We feel Knoxavarin is a promising therapy for alleviating symptoms and delaying neurodegeneration in CTE,”

James Cardwell
Emerald Rush Holdings Inc.
(408) 637-7847
email us here